Laval, Quebec (April 7, 2017) — Sanofi Canada announces, all new and existing Canadian patients prescribed Renagel® or Renvela®, will have access to RenassistPLUS, a patient support and reimbursement program aimed to help patients and their health care team get the most out of their personalized treatment plan.

“This will allow all Canadian patients who’ve come to rely upon Renagel® or Renvela® to be able to stay with their prescribed treatment and maintain treatment continuity,” says Tracey Ramsay, Head of General Medicine and Established Products, North America, Sanofi. “Providing valuable solutions is core to our purpose and this program is a great example of how Sanofi is doing its part to help improve the lives of patients.”

Eligible patients who are enrolled in RenassistPLUS are offered the opportunity to receive educational materials on the management of their disease, to obtain reimbursement assistance and to provide their physicians with an update on their treatment progress. RenassistPLUS offers these benefits at no cost to enrolled patients.

Patients are assigned their own Benefit Coordinator, who works with them to get the drug coverage they are entitled to, by means of financial support to meet co-pay or deductible payment requirements. RenassistPLUS provides access to a support team of nurses and dietitians in order to help patients stay on their prescribed treatment regimen. In addition, the program offers home drug delivery to patients and the freedom to select the pharmacy of their choice.

 “The RenassistPLUS Patient Assistance Program makes a big difference in helping patients’ access and stay on their prescribed treatment,” said Lissa Palmer, Program Coordinator, RenassistPLUS Patient Assistance Program. “RenassistPLUS provides a service that complements the work of the Renal Care team in order to navigate treatment and lead to better health outcomes.”

RenassistPLUS Patient Assistance Program – a commitment to patients

The RenassistPLUS Reimbursement and Patient Support program is available to any patient in Canada who is prescribed Renagel® or Renvela® by their treating Specialist.  Interested individuals can find out more about RenassistPLUS by visiting www.renassistplus.ca, by calling Medicum at 1-866-424-8051 or by speaking with healthcare provider.

About Sanofi – www.sanofi.ca

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi entities in Canada include the Diabetes and Cardiovascular Care Business Unit, the General Medicines and Established Products Business Unit, Sanofi Pasteur (vaccines), Sanofi Genzyme (specialty care) and Sanofi Consumer Health. Together they employ close to 1,900 people. In 2015 Sanofi companies invested $133.3 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

-30-

For more information:
Lissa Palmer
Sr. Program Coordinator
Medicum
lissap@medicum.ca
1-866-424-8051

Nadia Rahman
Communications
Sanofi Canada
nadia.rahman@sanofi.com
514-856-8754